HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Slovakia Down-Schedules CBD As WHO Insists It Is Not A Narcotic

Executive Summary

As a recent meeting of the United Nation's Commission on Narcotic Drugs, the World Health Organization recommended that CBD products with no more than 0.2% THC should not be considered controlled substances. In response, Slovakia down-scheduled CBD. The move and the discussion sparked by WHO's recommendation within the UN 's drug commission shines a new light on debates raging in the UK, where industry is currently facing claims that CBD products with any levels of THC whatsoever should be considered a controlled substance.

You may also be interested in...



EU CBD Market Under Threat With Narcotic Classification Favored

Leaning towards classifying CBD as a narcotic, the European Commission could dash hopes of a regulated EU market for dietary supplements containing the cannabinoid. 

Slovakian Government Rejects CBD Decriminalization

Cannibidiol (CBD) remains a scheduled drug in Slovakia after the country's parliament rejected a recent proposal to decriminalize the substance. 

Patience Wins The Race: TTS Pharma's CEO On Bringing The First Legal CBD Oil To The UK Market

TTS Pharma wants to be the first to launch a legal CBD oil onto the UK wellness market. TTS CEO Mark Tucker explains how his firm's CBD is produced according to strict standards and can provide a model for future regulation. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149167

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel